trial · primary record
Ranibizumab
Neovascular Age-related Macular Degeneration (nAMD)
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 451 |
| Primary completion | 2027-02-04 |
| Primary endpoint | Change from baseline in Best-corrected visual acuity (BCVA) score averaged over Weeks 68 and 72, as assessed using the ETDRS chart starting at a distance of 4 meters |
| Registry ID | NCT04657289 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:11.597Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04657289
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- RANIBIZUMAB · approval
- Ranibizumab · compound